Reconstruction and flux-balance analysis of the Plasmodium falciparum metabolic network.

Center for Computational Biology and Bioinformatics, Columbia University, New York City, NY 10032, USA.
Molecular Systems Biology (Impact Factor: 14.1). 09/2010; 6:408. DOI: 10.1038/msb.2010.60
Source: PubMed

ABSTRACT Genome-scale metabolic reconstructions can serve as important tools for hypothesis generation and high-throughput data integration. Here, we present a metabolic network reconstruction and flux-balance analysis (FBA) of Plasmodium falciparum, the primary agent of malaria. The compartmentalized metabolic network accounts for 1001 reactions and 616 metabolites. Enzyme-gene associations were established for 366 genes and 75% of all enzymatic reactions. Compared with other microbes, the P. falciparum metabolic network contains a relatively high number of essential genes, suggesting little redundancy of the parasite metabolism. The model was able to reproduce phenotypes of experimental gene knockout and drug inhibition assays with up to 90% accuracy. Moreover, using constraints based on gene-expression data, the model was able to predict the direction of concentration changes for external metabolites with 70% accuracy. Using FBA of the reconstructed network, we identified 40 enzymatic drug targets (i.e. in silico essential genes), with no or very low sequence identity to human proteins. To demonstrate that the model can be used to make clinically relevant predictions, we experimentally tested one of the identified drug targets, nicotinate mononucleotide adenylyltransferase, using a recently discovered small-molecule inhibitor.

1 Follower
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Malaria is a devastating parasitic disease, causing more than 600,000 deaths annually. Drug resistance has rendered previous generation anti-malarials ineffective and is also rapidly emerging against the current therapeutics of choice, artemisinin and its derivatives, making the discovery of new anti-malarials with novel mechanisms of action a priority. The Coenzyme A (CoA) synthesis pathway, a well-known anti-microbial drug target that is also essential for the malaria parasite Plasmodium falciparum, has not yet been exploited in anti-malarial drug development. A novel high throughput approach for the identification of chemically diverse inhibitors of the CoA synthesis pathway is reported.
    Malaria Journal 08/2014; 13(1):343. DOI:10.1186/1475-2875-13-343 · 3.49 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Metabolism is known for its intricate adjustments to meet the needs of an organism. Due to demands of adaptation, parasite metabolic pathways are greatly altered from those of their hosts. A key difference in metabolic pathways in Plasmodium spp, during the in-tra-erythrocytic stages, pertains to energy metabolism with the absence of a major role for the mitochondria in adenosine triphosphate (ATP) generation. In most organisms there exists a tight link between nucleotide and energy metabolism. An important feature of purine nucleotide metabolism in Plasmodium falcipa-rum is the absence of the de novo pathway, with purine requirements being completely met by the sal-vage pathway. Presence of the enzymes adenylosucci-nate lyase, adenylosuccinate synthetase and adenosine monophosphate (AMP) deaminase, involved in AMP metabolism, suggests the existence of a functional purine nucleotide cycle (PNC) in P. falciparum with fumarate, a tricarboxylic acid (TCA) cycle intermedi-ate, and ammonia being the net output from the cycle. In the absence of a conventional TCA cycle, the fate of fumarate generated from PNC merits examination. In this review we cover ATP generation through glycoly-sis, key features of the TCA cycle, the role of electron transport chain and the link between PNC and the mitochondrion. Recent studies using genetic appro-aches highlight unexpected features that were hitherto unknown with respect to these pathways and these are also summarized in this review.
    Current science 10/2012; · 0.83 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background: The paradigm of resistance evolution to chemotherapeutic agents is that a key coding mutation in a specific gene drives resistance to a particular drug. In the case of resistance to the anti-malarial drug chloroquine (CQ), a specific mutation in the transporter pfcrt is associated with resistance. Here, we apply a series of analytical steps to gene expression data from our lab and leverage 3 independent datasets to identify pfcrt-interacting genes. Resulting networks provide insights into pfcrt's biological functions and regulation, as well as the divergent phenotypic effects of its allelic variants in different genetic backgrounds. Results: To identify pfcrt-interacting genes, we analyze pfcrt co-expression networks in 2 phenotypic states-CQ-resistant (CQR) and CQ-sensitive (CQS) recombinant progeny clones-using a computational approach that prioritizes gene interactions into functional and regulatory relationships. For both phenotypic states, pfcrt co-expressed gene sets are associated with hemoglobin metabolism, consistent with CQ's expected mode of action. To predict the drivers of co-expression divergence, we integrate topological relationships in the co-expression networks with available high confidence protein-protein interaction data. This analysis identifies 3 transcriptional regulators from the ApiAP2 family and histone acetylation as potential mediators of these divergences. We validate the predicted divergences in DNA mismatch repair and histone acetylation by measuring the effects of small molecule inhibitors in recombinant progeny clones combined with quantitative trait locus (QTL) mapping. Conclusions: This work demonstrates the utility of differential co-expression viewed in a network framework to uncover functional and regulatory divergence in phenotypically distinct parasites. pfcrt-associated co-expression in the CQ resistant progeny highlights CQR-specific gene relationships and possible targeted intervention strategies. The approaches outlined here can be readily generalized to other parasite populations and drug resistances.
    BMC Genomics 02/2015; 16(1):115. DOI:10.1186/s12864-015-1261-6 · 4.04 Impact Factor

Full-text (2 Sources)

Available from
Aug 5, 2014